JPRN-UMIN000013424
Completed
Phase 1
Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients - Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Saitama Medical Center
- Enrollment
- 6
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional,observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2\)plueral, peritoneal, or pericardial effusion requiring drainage 3\)active infection 4\)unable to take oral medication 5\)symptomatic eye disorders 6\)pregnant or lactating 7\)symptomatic brain metastasis 8\)other malignancies 9\)uncontrolled diabetes 10\) active complications 11\)patients whom physicians judged to be unsuitable for enrollment for other reasons
Investigators
Similar Trials
Recruiting
Not Applicable
Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung canceradvanced or recurrent non-small-cell lung cancerJPRN-UMIN000006892School of Medicine, Keio University12
Active, not recruiting
Not Applicable
Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer. - tarcevapancreasPatients with unresectable advanced or metastatic pancreatic cancerMedDRA version: 6.1Level: PTClassification code 10033609EUCTR2006-001238-41-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
Not yet recruiting
Phase 2
To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.on-Small-Cell Lung CancerJPRN-UMIN000012515Department of Respiratory Medicine, Kumamoto University Hospital16
Completed
Not Applicable
Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000012862Shizuoka cancer center70
Completed
Phase 2
A randomized phase II study of Erlotinib with or without Bevacizumab in NSCLC patients previouly treated with platinum-based chemotherapy containing bevacizumab. North Japan Lung Cancer Study Group Trial 1201JPRN-UMIN000007475orth Japan Lung Cancer Study Group64